The EXO-CD24 nasal spray saw a near 100% success rate in Phase I clinical trials, which will also be expanded to Greece’s largest hospital.

The EXO-CD24 nasal spray saw a near 100% success rate in Phase I clinical trials, which will also be expanded to Greece’s largest hospital.